Asthma is an increasingly common chronic respiratory condition that affects millions worldwide. It is characterized by airway inflammation and hyper-responsiveness, leading to recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing. For many patients, traditional methods of management remain inadequate. This is where inhaled therapies enter the picture, providing a more direct and often more effective means of controlling symptoms and improving quality of life.

The review systematically explores the mechanism of action of inhaled therapies, particularly focusing on corticosteroids and bronchodilators. Corticosteroids work by reducing inflammation in the airways, which is a critical component of asthma pathology. This reduction in inflammation leads to decreased airway hyper-responsiveness, which can significantly enhance airflow and alleviate symptoms. Meanwhile, bronchodilators act to relax the muscles surrounding the airways, providing immediate relief from the acute symptoms associated with asthma attacks.

One of the key advancements in inhaled therapy is the development of novel inhalation devices that optimize drug delivery. These devices are designed to enhance the deposition of medication directly in the lungs, ensuring that patients receive the maximal therapeutic benefit. Studies referenced in the review highlight that proper inhaler technique is crucial for effective therapy. Inadequate inhalation techniques can severely compromise drug delivery, underscoring the need for continuous patient education and training.

The review also tackles the importance of personalized medicine in asthma management. Identifying the specific type of asthma a patient has—whether it’s allergic, non-allergic, or exercise-induced—can drastically change the treatment landscape. By understanding the underlying triggers and pathology, healthcare providers can tailor inhaled therapies that are more effective for individual patients, leading to improved outcomes.

Importantly, the narrative review includes a detailed examination of patient responses to inhaled therapy through various visualizing techniques. These innovative methods reveal not just symptom relief but also observable changes in airway size and inflammation levels. Technologies such as imaging and biomarker analysis are crucial in evaluating treatment success, offering a tangible measure of how inhalation therapies restore normal function to constricted airways.

However, the narrative also brings to light the barriers faced by patients in accessing inhaled therapies. Despite their efficacy, not all patients have equal access to these treatments due to socioeconomic factors, healthcare disparities, and patient education. The authors advocate for systemic changes that prioritize equitable access to asthma care, emphasizing that these therapies should be available to all segments of the population, not just those with favorable circumstances.

Another fascinating aspect discussed in the review is the role of adherence to prescribed inhaled therapies. Non-adherence remains a significant challenge in asthma management. The article reviews recent studies exploring the reasons behind medication non-adherence, ranging from forgetfulness to complex dosing schedules. Addressing these barriers is critical for improving overall health outcomes, as demonstrated by patients who have successfully integrated their inhaled therapy into their daily routines.

Moreover, the psychological dimension of asthma management is brought to the forefront. The emotional burden of living with uncontrolled asthma can weigh heavily on patients. The review highlights the importance of integrating mental health support with physical health treatments, advocating for a holistic approach to asthma management that recognizes the interplay between the two.

In closing, Tcherner et al. provide an imperative call to action for clinicians and researchers alike. The importance of ongoing research in this field can not be understated, as it will pave the way for more effective and innovative inhalation therapies tailored to the evolving landscape of asthma management. By continuing to explore the intricacies of airway dysfunction and the myriad factors that influence treatment efficacy, the medical community can enhance the quality of life for all patients suffering from this chronic condition.

The hope is that through further advancements and a collaborative approach to asthma care, patients will have access to the best possible therapies that lead to significant improvements in their daily lives. This narrative review acts as a pivotal contribution, underpinning the need for comprehensive strategies in the realm of inhaled therapies.

Ultimately, the call for further innovations in inhaled therapies, coupled with a deeper understanding of patient needs and systemic barriers, stands to revolutionize asthma care in the coming years. The pathway to effectively visualizing improvements in airway dysfunction after employing inhaled therapies signifies a monumental step toward better, more personalized asthma treatment strategies.

Subject of Research: Inhaled therapy and airway dysfunction in asthma management.

Article Title: Visualizing Improvements in Airway Dysfunction After Inhaled Therapy in Patients With Uncontrolled Asthma: A Narrative Review.

Article References:

Tcherner, S., Mozaffaripour, A., Yamashita, C. et al. Visualizing Improvements in Airway Dysfunction After Inhaled Therapy in Patients With Uncontrolled Asthma: A Narrative Review.
Adv Ther (2025). https://doi.org/10.1007/s12325-025-03392-4

Image Credits: AI Generated

DOI: 10.1007/s12325-025-03392-4

Keywords: asthma management, inhaled therapy, airway dysfunction, personalized medicine, patient adherence.

Allergic asthma remains a chronic respiratory condition marked by airway hyperresponsiveness, excessive mucus production, and infiltration of inflammatory cells such as eosinophils and T helper 2 (Th2) lymphocytes. Central to the disease’s pathogenesis is the dysregulated activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinases (MAPKs), including the p38 pathway, both of which orchestrate the transcription of pro-inflammatory mediators. By attenuating these pathways, Perilla frutescens var. acuta ushers in a wave of anti-inflammatory events that could mitigate the severity of allergic asthma and potentially modify its chronic trajectory.

This revelation stems from meticulous experiments employing murine models sensitized with ovalbumin to mimic human allergic asthma. Researchers administered extracts of Perilla frutescens var. acuta and observed a pronounced reduction in airway inflammation, evaluated through histological assessments that revealed decreased eosinophilic infiltration and diminished mucosal thickening. Complementary molecular analyses indicated that treatment effectively suppressed NF-κB nuclear translocation and phosphorylation of p38 MAP kinase, disrupting the cascade responsible for cytokine production and immune cell recruitment in the airways.

What sets this botanical intervention apart is not only its efficacy but also its specificity in targeting signaling pathways without broadly suppressing the immune system, a frequent complication in current therapeutic regimens. Conventional asthma medications, particularly corticosteroids, though effective, come hand-in-hand with adverse immunosuppressive side effects. The selective modulation of NF-κB and p38 by Perilla frutescens extracts thus offers a promising therapeutic window that balances efficacy and safety.

Bioactive constituents believed to underlie these anti-inflammatory mechanisms include a spectrum of phenolic compounds, flavonoids, and rosmarinic acid derivatives intrinsic to Perilla frutescens. These phytochemicals have known antioxidant properties and an ability to modulate signal transduction cascades by interacting with kinases and transcription factors. The study’s findings suggest these compounds synergize to inhibit the phosphorylation events critical for activating inflammatory gene expression, thereby attenuating the downstream secretion of IL-4, IL-5, and IL-13 cytokines intimately involved in eosinophil attraction and IgE production.

The suppression of the NF-κB pathway is particularly noteworthy because NF-κB acts as the gatekeeper of numerous inflammatory genes, including those encoding for cytokines, chemokines, and adhesion molecules. The study revealed that extract treatment prevented the degradation of IκBα, an inhibitor protein that retains NF-κB in the cytoplasm, thus curtailing its capacity to translocate into the nucleus and propagate inflammatory signaling. Simultaneously, inhibiting p38 MAP kinase activity interrupts stress-activated signaling that amplifies cytokine gene transcription, further dampening inflammatory amplification loops.

Beyond cellular signaling observations, functional assessments measured respiratory parameters indicative of airway hyperreactivity. Mice receiving Perilla frutescens var. acuta extracts displayed significantly improved lung function, with reduced airway resistance and enhanced airflow following allergen challenge. These physiological improvements correlated well with molecular findings, collectively underscoring the therapeutic potential of this plant extract in restoring respiratory homeostasis disturbed in allergic asthma.

Furthermore, the safety profile of the botanical treatment was rigorously evaluated. Unlike broad-spectrum immunosuppressants, administration of Perilla frutescens extracts did not perturb systemic immune parameters or induce cytotoxicity in bronchial epithelial cells, adding to the appeal of this herbal approach for long-term management of asthma. The prospect of integrating such phytotherapeutics into existing treatment paradigms points toward an era where plant-derived bioactives complement or offer alternatives to synthetic drugs.

The implications of these findings extend beyond asthma management. Given the central role of NF-κB and p38 MAPK pathways in various chronic inflammatory and autoimmune diseases, Perilla frutescens var. acuta may emerge as a candidate for wider applications in inflammatory disorders. Its influence on key intracellular pathways posits it as a molecular modulator worthy of exploration in conditions characterized by aberrant inflammation including rheumatoid arthritis, inflammatory bowel disease, and even certain cancers.

Moreover, this research underscores the invaluable contribution of ethnobotany and traditional medicine to contemporary pharmacology. Perilla’s historical application in treating respiratory and allergic conditions provides a biological rationale supported today by rigorous scientific validation. The journey from folk remedy to molecularly elucidated therapeutic agent exemplifies the translational power of integrating ancient wisdom with modern biomedical research.

While promising, future investigation is warranted to isolate and characterize individual compounds responsible for Perilla frutescens’ bioactivity and to optimize dosing strategies. Clinical trials will be essential to confirm efficacy and safety in human populations, understand pharmacokinetics, and evaluate long-term outcomes. Additionally, mechanistic studies employing gene knockouts or pathway-specific inhibitors could further clarify the molecular interplay governing the extract’s anti-inflammatory effects.

This study exemplifies a paradigm shift towards harnessing nature’s pharmacopoeia to tackle complex immunological diseases. The intersection of molecular biology, pharmacognosy, and clinical research paves the way for novel, safer, and more sustainable therapies. With allergic asthma affecting millions globally and healthcare systems facing burdens of chronic disease management, Perilla frutescens var. acuta offers a beacon of hope for more effective and less harmful treatment modalities.

In conclusion, by elucidating the capacity of Perilla frutescens Britton var. acuta Kudo to ameliorate allergic asthma via suppression of NF-κB and p38 signaling pathways, this research charts a promising course for plant-derived therapeutics against respiratory inflammation. The convergence of traditional knowledge and cutting-edge science manifested in this work inspires optimism for addressing unmet clinical needs through nature-inspired innovation.

Subject of Research: Perilla frutescens Britton var. acuta Kudo’s effects on OVA-induced allergic asthma through modulation of intracellular inflammatory signaling pathways.

Article Title: Perilla frutescens Britton var. acuta Kudo ameliorates OVA-induced allergic asthma via inhibiting NF-κB and p38 signaling pathways.

Article References:
Choi, J., Yoo, E.B., Park, J. et al. Perilla frutescens Britton var. acuta Kudo ameliorates OVA-induced allergic asthma via inhibiting NF-κB and p38 signaling pathways. Food Sci Biotechnol (2025). https://doi.org/10.1007/s10068-025-01968-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10068-025-01968-y